Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-12
2011-07-12
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07977335
ABSTRACT:
The present invention provides a method of preventing or reducing the severity of a stress-associated condition in a subject by systemically administering to the subject an effective amount of brimonidine or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. Stress-associated conditions that can be treated according to a method of the invention include, but are not limited to, dyspepsia, tachycardias other than tachycardia associated with myocardial ischemia, panic attack, non-inflammatory dermatological conditions, disorders of muscle contraction, sensory hypersensitivity associated with migraine, and behavioral disorders.
REFERENCES:
patent: 5795909 (1998-08-01), Shashoua et al.
patent: 6444681 (2002-09-01), Flavahan et al.
patent: 6576636 (2003-06-01), Webb et al.
patent: 6602902 (2003-08-01), Shashoua et al.
patent: 7160890 (2007-01-01), Castelhano et al.
patent: 2003/0059471 (2003-03-01), Compton et al.
patent: 2003/0073708 (2003-04-01), Castelhano et al.
patent: 2004/0242588 (2004-12-01), Dejovin et al.
patent: 2005/0276830 (2005-12-01), Dejovin et al.
patent: 2006/0171974 (2006-08-01), Dejovin et al.
patent: 2006/0264515 (2006-11-01), Dejovin et al.
patent: 188750 (2002-11-01), None
patent: WO96-25163 (1996-08-01), None
patent: WO99-30690 (1999-06-01), None
patent: WO00-24375 (2000-05-01), None
patent: WO00-76502 (2000-12-01), None
patent: WO00-76520 (2000-12-01), None
patent: WO03-048120 (2003-06-01), None
patent: WO2005-010025 (2005-02-01), None
patent: WO2005-115395 (2005-12-01), None
Watts et al. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure. Eye, Mar. 2002, vol. 16, No. 2 pp. 132-135, abstract.
Flavahan et al, “Increased alpha2-Adrenergic Constriction of Isolated Arterioles in Diffuse Scleroderma”, Arthritis & Rheumatism, vol. 43, No. 8, pp. 1886-1890, Aug. 2000.
Flavahan et al, “Sympathetic Purinergic Vasoconstriction and Thermosensitivity in a Canine Cutaneous Vein”, J. Pharmacol. Exp. Ther. 239, No. 3, 784-89, 1986.
Flavahan et al, “Cooling and Alpha-1- and Alpha2-Adrenergic Responses in Cutaneous Veins: Role of Receptor Reserve”, Am. J. Physiol. No. 5, H950-H955, 1985.
Vanhoutte et al, “Modulation of Postjunctional Alpha-Adrenergic Responsiveness by Local Changes in Temperature”, Clin. Sci., 68 (Suppl 10), 121S-23S, 1985.
Pollock et al, “Control of arteriovenous anastomoses in rabbit ear model of digital perfusion”, The American Journal of Physiology, vol. 271, No. 5, pp. H-2007-13, 1996.
Chotani et al, “Silent alpha (2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries”, American Journal of Physiology-Heart and Circulatory Physiology, vol. 278, No. 4, 47-4, pp. H1075-H1083, 2000.
Fuchs et al, “Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin”, Pain: 90(1-2), 15-23, 2001.
Clouse et al, “Short-term treatment with transdermal nicotine affects the function of canine saphenous veins”, Vascular medicine, vol. 5, No. 2, pp. 75-82, 2000.
Sodhi et al, “Dermatological side effects of brimonidine: A report of three cases”, Journal of Dermatology, vol. 30, No. 9, pp. 697-700, 2003.
Watts et al, “Delayed hypersensitivity to brimonidine tartrate 0.2 % associated with high intraocular pressure”, Eye, vol. 16, No. 2, pp. 132-135, 2002.
Blondeau et al, “Allergic reactions to brimonidine in patients treated for glaucoma”, Canadian Journal of Opthalmology, vol. 37, No. 1, pp. 21-26, 2002.
Supplemental Response to Sep. 20, 2007 Office Action and Sustance of the Intervies Under 37 CFR 1.133(b)-SN U.S. Appl. No. 10/853,586.
Declaration Under 37 CFR 1.132 in U.S. Appl. No. 10/853,585, Jan. 8, 2008.
Office Communication Date Mailed Sep. 20, 2007 in U.S. Appl. No. 10/853,585.
Response to Final Office Action Dated Sep. 20, 2007 in U.S. Appl. No. 10/853,585.
Brin Mitchell F.
Donello John E.
Gil Daniel W.
Whitcup Scott
Allergan Inc.
Allergan, Inc.
Condino Debra D.
German Joel B.
Kim Jennifer M
LandOfFree
Methods of preventing and reducing the severity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of preventing and reducing the severity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preventing and reducing the severity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740053